Analyst Price Target is C$3.18
▼ -59.03% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Medexus Pharmaceuticals in the last 3 months. The average price target is C$3.18, with a high forecast of C$4.00 and a low forecast of C$2.35. The average price target represents a -59.03% upside from the last price of C$7.75.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Medexus Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.